חוב כולל של החברה: shuttlepharma.com (SHPH)

The development of radiosensitizers for brain tumor therapy remains independent of economic cycles, as evidenced by the price action reflecting the 0.00 indicator for Shuttle Pharmaceuticals (SHPH). The business relies on robotic cell analysis for deep research without expanding headcount. Furthermore, Shuttle Pharmaceuticals (SHPH) delegates clinical trials to external CRO partners while maintaining exclusive control over all patents and the unique formulas of the molecules being developed.

Developing drugs to increase tumor sensitivity to radiation in partnership with oncology centers requires significant R&D capital expenditures. This indicator aggregates the total borrowed obligations of Shuttle Pharmaceuticals (SHPH), allowing for a comparison between the pace of credit expansion and margin growth to assess financial stability, which clearly reflects changes in the debt load.